Spectrum of malignancies among HIV-infected patients in South India.
Indian J Cancer
;
2012 Jan-Mar; 49(1): 176-180
Artículo
en Inglés
| IMSEAR
| ID: sea-144568
ABSTRACT
Introduction:
The current study examines the spectrum of malignancies among HIV-infected South Indians enrolled in a clinical care program. Materials andMethods:
We conducted a nested matched case-control study among 42 HIV-infected cases who developed cancer and 82 HIV-infected controls between 1998 and 2008 at a tertiary care HIV care program in South India.Results:
The most common types of cancer included non-Hodgkin's lymphoma (38.1%), Hodgkin's lymphoma (16.7%), squamous cell carcinoma (14.3%), and adenocarcinoma (14.3%). The median duration of time from HIV infection to cancer diagnosis was 549 days [interquartile range (IQR) 58-2013]. The nadir CD4 cell count was significantly lower in cases compared to controls (134 cells/μl vs. 169 cells/μl; P = 0.015). Cancer patients were more likely to have a more advanced HIV disease stage at the time of cancer diagnosis compared to control patients (Stage C 90.5% vs. 49.4%; P<0.0001). Significantly more cancer patients were receiving antiretroviral treatment relative to control patients at the time of cancer diagnosis (92.9% vs. 66.3%; P=0.001).Conclusions:
HIV-infected patients who developed cancer had more advanced immunodeficiency at the time of cancer diagnosis and a lower nadir CD4 cell count. It is possible that with the continued roll-out of highly active antiretroviral therapy in India, the incidence of HIV-associated malignancies will decrease.
Texto completo:
Disponible
Índice:
IMSEAR (Asia Sudoriental)
Asunto principal:
Linfoma no Hodgkin
/
Femenino
/
Humanos
/
Enfermedad de Hodgkin
/
Carcinoma de Células Escamosas
/
Adenocarcinoma
/
Estudios de Casos y Controles
/
Infecciones por VIH
/
Recuento de Linfocito CD4
/
Adulto
Tipo de estudio:
Estudio observacional
/
Factores de riesgo
País/Región como asunto:
Asia
Idioma:
Inglés
Revista:
Indian J Cancer
Año:
2012
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS